ALBO News and Press, Albireo Pharma Inc. From 12/09/21

BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year after almost ...

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the appointment of Constantine Chinoporos as Chief Business Officer and a member of the Albireo Enterprise Leadership Team. Mr. ...

Albireo developed Odevixibat - a product as a pipeline - as a life-saving therapy for multiple ultra-rare pediatric liver disease indications. Following the approval of Odevixibat in PFIC, Albireo needs to transform into a commercial company capable of generating profits. Albireo ...

– Evidence of long-term clinical treatment benefit of Bylvay™ (odevixibat) showing improved liver health and function across PFIC types – – Data show Bylvay therapy up to 128 weeks, sustained improvements in hepatic health, quality of sleep and g...

Mirum recently won approval for Livmarli in Alagille syndrome, a rare liver disorder with a market opportunity of ~$1bn. The company is heavily loss making, but has >$230m in cash which it says will be sufficient for 3 years. There is plenty of opportunity to expand the label o...

Image source: The Motley Fool. Albireo Pharma, inc (NASDAQ: ALBO) Q3 2021 Earnings Call Nov 4, 2021 , 10:00 a.m. ET Operator Continue reading For further details see: Albireo Pharma, inc (ALBO) Q3 2021 Earnings Call Transcript

Albireo Pharma, Inc. (ALBO) Q3 2021 Earnings Conference Call November 04, 2021, 10:00 AM ET Company Participants Paul Arndt - Managing Director of LifeSci Advisors Ron Cooper - President and CEO Simon Harford - CFO Pamela Stephenson - CCO Pat Horn - Chief Medical Officer Conference Call Parti...

Albireo Pharma (NASDAQ:ALBO): Q3 GAAP EPS of $2.90 beats by $2.41. Revenue of $3.67M (+72.3% Y/Y) misses by $13.38M. Press Release For further details see: Albireo Pharma EPS beats by $2.41, misses on revenue

– Bylvay™ (odevixibat) approved in the U.S. and Europe, partial Q3 ’21 revenue of $1.1 million – – ASSERT & BOLD Phase 3 studies enrolling, on track for topline data readouts – – 12 abstracts accepted at ...

ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...